Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 7,455 matching trials from the live ClinicalTrials.gov search.

Filters: Denver, Colorado Clear all

Conditions: Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions: Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 171
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Anemia, Mortality
Interventions: Early anemia diagnosis and treatment, No change from normal routine; Other
Lead sponsor: Fresenius Medical Care North America; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: JBI-802; Drug
Lead sponsor: Jubilant Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 638
States / cities: Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more

Conditions: Hypogonadism
Interventions: Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Food Allergy in Children
Interventions: Skin tape stripping, Skin barrier assessment, Blood draw; Diagnostic Test · Device
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Frail Older Adults
Interventions: Progressive Multi-Component Intervention, Usual Care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Aurora, Colorado • Glenside, Pennsylvania

Conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2027
U.S. locations: 140
States / cities: Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more

Conditions: Sepsis, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection
Interventions: Drotrecogin Alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 5
States / cities: Denver, Colorado • Iowa City, Iowa • Manhassaet, New York + 2 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Placebo, BFKB8488A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 39
States / cities: Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 30 more

Conditions: Chronic Heart Failure
Interventions: CASA Intervention; Other
Lead sponsor: Denver Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
Interventions: Cohort B: paridiprubart, Cohort B: placebo; Drug
Lead sponsor: PPD Development, LP; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 34 more

Conditions: Desmoplastic Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Positron Emission Tomography, Therapeutic Conventional Surgery; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 280
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 199 more

Conditions: Migraine
Interventions: Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 82
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more

Conditions: Epilepsy, Localization-related Epilepsy, Infantile Spasms, Lennox-Gastaut Syndrome, Polymicrogyria, Periventricular Heterotopias
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 4 Weeks to 60 Years
Enrollment: 4,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 19 more

Conditions: Sleep Disorder
Interventions: CPC M1; Device
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Advanced Solid Tumors or Lymphomas
Interventions: CA-170; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Sarasota, Florida + 7 more

Conditions: Obesity
Interventions: Sitagliptin Phosphate; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lung Carcinoma
Interventions: Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Colorectal Cancer
Interventions: cetuximab, Irinotecan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 116
States / cities: Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more

Conditions: Venous Thrombosis
Interventions: PD 0348292, Enoxaparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more

Search by objective public record fields.

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Cardiovascular Outcomes of Low Testosterone

Skin Characteristics of Parents of Food Allergic Pediatric Patients

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Acute Treatment Trial in Adult Subjects With Migraines

Epilepsy Phenome/Genome Project

Study Comparing In-laboratory Polysomnography Electrocardiogram (PSG ECG) to Simultaneously Recorded In-laboratory ECG on the CPC M1 Device

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Incretin Effect in People With Impaired Fasting Glucose

Iloprost in Preventing Lung Cancer in Former Smokers

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery